Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies
News
Neglected rare disease patients offered hope in new plan
Unmet need among over 7000 rare diseases is being addressed in a comprehensive action plan
CHMP provides initial assessment of Valneva’s COVID-19 vaccine
Valneva expects to receive a positive CHMP recommendation for the conditional approval of its VLA2001 vaccine
Community pharmacies save 20,000 lives during initial vaccination phases
Figures by National Audit Office estimate that programme prevented up to 262,000 hospitalisations
Data from first DMT-assisted clinical trial revealed
No sign of significant negative effects on anxiety and wellbeing following pioneering Small Pharma trial
Data delivery: Sanofi and GSK seek authorisation for COVID-19 vaccine
Pharma giants take major stride as vaccine shows significant increase in neutralising antibodies
Greater tolerance: Allergic reactions to COVID vaccine lower for second dose
Researchers discovered that recipients experiencing an allergic response to second COVID vaccine dose are minimal
Haleon days: GSK explains demerger decision
New company Haleon will become standalone venture as GSK’s strategy for the future unfolds
Victory Road: NHS successful in 11 year claim against Servier
The European Commission finds that Servier committed a breach of competition over blood pressure drug
PANORAMIC view of World’s largest COVID study
Study involving 10,000 patients will investigate a range of potentially ground-breaking oral antivirals
UK health leaders call for urgent mental healthcare plan
The UK government is urged to be more mindful of children and young people who have mental health issues, following the publication of the NHS Elective Recovery Plan
NHS gene testing fails half of people at cancer risk
Study reveals that many with an increased risk of cancer were excluded from the potential for monitoring
Data day: Trial results deliver hope for prostate cancer patients
New combination treatment can significantly reduce the risk of death among prostate cancer patients
All trades: Syncona announces sale of portfolio company to Novartis
Company focused on founding and building global leaders in life science sold to Novartis
Moderna’s commercial network grows
Vaccine pioneers expand presence throughout Europe with a view to leveraging technology
